SEC Form 4 · accession 0001209191-16-107907
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert F Apple
Officer — President & CEO · Director
Period of report
Mar 10, 2016
Accepted (ET)
Mar 11, 2016 · 5:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1,F2 | $0.88 | Mar 10, 2016 | A | 250,000 | A | — | Mar 9, 2026 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan.
- F2The options vest in equal quarterly installments over three years from the date of grant.